MiNK Therapeutics INKT Income Statement (2020-2026)

NASDAQ INKT
$12.26 +0.15 (+1.24%)
At close: Sep 29, 2026 · 4:00 PM EDT
Reported Financials

MiNK Therapeutics Quarterly Income Statement

Periods 24 quarters
Latest Jun 2026

MiNK Therapeutics reported net income of -$3.14M for the quarter ended Jun 2026. This income statement covers 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
2.42M2.60M3.36M3.38M3.38M3.39M3.44M3.45M3.45M3.46M3.47M3.95M3.95M3.96M3.99M4.52M4.69M4.71M4.98M5.10M
Operating items
Research & DevelopmentR&D
3.33M3.95M5.28M5.88M6.15M5.81M4.19M4.56M3.43M3.31M2.55M1.84M0.54M1.41M1.26M1.84M1.14M1.51M1.20M1.89M
Selling, General & AdministrativeSG&A
0.81M2.36M2.10M1.82M1.84M2.08M1.66M1.78M1.80M2.19M1.28M1.06M1.16M0.81M1.27M1.85M1.85M1.76M1.68M1.33M
Operating ExpensesOpex
4.15M6.31M7.37M7.70M7.99M7.89M5.85M6.34M5.22M5.50M3.83M2.90M1.70M2.21M2.53M3.69M2.99M3.28M2.88M3.22M
Operating IncomeOp. Inc
-13.38M-6.36M-7.37M-7.70M-7.99M-7.89M-5.85M-6.34M-5.22M-5.50M-3.83M-3.07M-1.89M-2.50M-2.70M-4.05M-3.18M-2.71M-2.88M-3.22M
EBIT
-13.38M-6.36M-7.37M-7.70M-7.99M-7.89M-5.85M-6.34M-5.22M-5.50M-3.83M-3.07M-1.89M-2.50M-2.70M-4.05M-3.18M-2.71M-2.88M-3.22M
Non-operating items
Non Operating Interest Expenses
0.88M0.81M848.00
Interest & Investment IncomeInt & Inv Inc
0.03M0.06M0.11M0.07M0.04M0.03M0.08M0.14M0.09M0.07M
Other Non Operating IncomeOther Non Op Inc.
-0.36M0.73M-0.40M1.56M1.56M-0.02M8.00-18.000.33M-0.08M-0.19M0.24M-0.01M0.06M0.02M
Net income details
EBT
-14.26M-7.17M-7.38M-7.70M-7.99M-7.89M-5.85M-6.34M-5.22M-5.50M-3.80M-3.01M-1.78M-2.43M-2.66M-4.03M-3.10M-2.57M-2.80M-3.14M
Profit After TaxPAT
-14.26M-7.17M-7.38M-7.70M-7.99M-7.89M-5.85M-6.34M-5.22M-5.50M-3.80M-3.01M-1.78M-2.43M-2.66M-4.03M-3.10M-2.57M-2.80M-3.14M
Income from Continuing OperationsIncome (Continuing)
-14.26M-7.17M-7.38M-7.70M-7.99M-7.89M-5.85M-6.34M-5.22M-5.50M-3.80M-3.01M-1.78M-2.43M-2.66M-4.03M-3.10M-2.57M-2.80M-3.14M
Consolidated Net IncomeConsol Net Inc.
-14.26M-7.17M-7.38M-7.70M-7.99M-7.89M-5.85M-6.34M-5.22M-5.50M-3.80M-3.01M-1.78M-2.43M-2.66M-4.03M-3.10M-2.57M-2.80M-3.14M
Income towards Parent CompanyParent Net Inc
-14.27M-5.76M-7.78M-6.11M-6.33M-7.77M-5.69M-6.20M-5.12M-5.46M-3.81M-2.70M-1.81M-2.46M-2.77M-4.24M-2.89M-2.60M-2.74M-3.13M
Net Income towards Common StockholdersNet Income
-14.27M-5.76M-7.78M-6.11M-6.33M-7.77M-5.69M-6.20M-5.12M-5.46M-3.81M-2.70M-1.81M-2.46M-2.77M-4.24M-2.89M-2.60M-2.74M-3.13M
Additional items
EPS (Basic)
-5.89-2.21-2.32-1.82-1.88-2.31-1.67-1.80-1.48-1.59-1.10-0.73-0.46-0.65-0.70-1.06-0.65-0.61-0.57-0.62
EPS (Diluted)
-5.89-2.21-2.32-1.82-1.88-2.31-1.67-1.80-1.48-1.59-1.10-0.73-0.46-0.65-0.70-1.06-0.65-0.61-0.57-0.62
Shares Outstanding
2.42M2.60M3.35M3.36M3.38M3.37M3.40M3.44M3.45M3.44M3.46M3.71M3.95M3.77M3.96M3.98M4.44M4.27M4.80M5.02M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
2.42M2.60M3.35M3.36M3.38M3.37M3.40M3.44M3.45M3.44M3.46M3.71M3.95M3.77M3.96M3.98M4.44M4.27M4.80M5.02M
EBITDA
-13.36M-6.34M-7.35M-7.67M-7.96M-7.85M-5.81M-6.29M-5.17M-5.45M-3.78M-3.03M-1.82M-2.45M-2.65M-4.00M-3.14M-2.67M-2.85M-3.18M
Interest ExpensesInt Expense
0.88M0.81M848.00

MiNK Therapeutics Income Statement API

Pull MiNK Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=INKT&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY